317 related articles for article (PubMed ID: 31469467)
21. Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Youssef O; Knuuttila A; Piirilä P; Böhling T; Sarhadi V; Knuutila S
Anticancer Res; 2018 Oct; 38(10):5627-5634. PubMed ID: 30275180
[TBL] [Abstract][Full Text] [Related]
22. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
23. Cancer driver mutations: predictions and reality.
Ostroverkhova D; Przytycka TM; Panchenko AR
Trends Mol Med; 2023 Jul; 29(7):554-566. PubMed ID: 37076339
[TBL] [Abstract][Full Text] [Related]
24. Targeted next-generation sequencing of 50 cancer-related genes in Japanese patients with oral squamous cell carcinoma.
Nakagaki T; Tamura M; Kobashi K; Omori A; Koyama R; Idogawa M; Ogi K; Hiratsuka H; Tokino T; Sasaki Y
Tumour Biol; 2018 Sep; 40(9):1010428318800180. PubMed ID: 30226113
[TBL] [Abstract][Full Text] [Related]
25. Analysis of in vivo mutation data can inform cancer risk assessment.
Moore MM; Heflich RH; Haber LT; Allen BC; Shipp AM; Kodell RL
Regul Toxicol Pharmacol; 2008 Jul; 51(2):151-61. PubMed ID: 18321622
[TBL] [Abstract][Full Text] [Related]
26. Molecular epidemiology in cancer risk assessment and prevention: recent progress and avenues for future research.
Wogan GN
Environ Health Perspect; 1992 Nov; 98():167-78. PubMed ID: 1486846
[TBL] [Abstract][Full Text] [Related]
27. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
28. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
Hayashi H; Kohno T; Ueno H; Hiraoka N; Kondo S; Saito M; Shimada Y; Ichikawa H; Kato M; Shibata T; Morizane C; Sakamoto Y; Shimada K; Komatsu Y; Sakamoto N; Okusaka T
Pancreas; 2017 Mar; 46(3):335-340. PubMed ID: 28099251
[TBL] [Abstract][Full Text] [Related]
29. Carcinogen-induced impairment of enzymes for replicative fidelity of DNA and the initiation of tumours.
Bignold LP
Carcinogenesis; 2004 Mar; 25(3):299-307. PubMed ID: 14604890
[TBL] [Abstract][Full Text] [Related]
30. Linking DNA adduct formation and human cancer risk in chemical carcinogenesis.
Poirier MC
Environ Mol Mutagen; 2016 Aug; 57(7):499-507. PubMed ID: 27346877
[TBL] [Abstract][Full Text] [Related]
31. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
[TBL] [Abstract][Full Text] [Related]
32. 1995 Deichmann Lecture--p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment.
Harris CC
Toxicol Lett; 1995 Dec; 82-83():1-7. PubMed ID: 8597035
[TBL] [Abstract][Full Text] [Related]
33. Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma.
Luo H; Li H; Hu Z; Wu H; Liu C; Li Y; Zhang X; Lin P; Hou Q; Ding G; Wang Y; Li S; Wei D; Qiu F; Li Y; Wu S
Biochem Biophys Res Commun; 2016 Mar; 471(4):596-602. PubMed ID: 26876573
[TBL] [Abstract][Full Text] [Related]
34. Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement.
Budczies J; Kazdal D; Allgäuer M; Christopoulos P; Rempel E; Pfarr N; Weichert W; Fröhling S; Thomas M; Peters S; Endris V; Schirmacher P; Stenzinger A
Lung Cancer; 2020 Apr; 142():114-119. PubMed ID: 32143116
[TBL] [Abstract][Full Text] [Related]
35. Role of epigenetic events in chemical carcinogenesis--a justification for incorporating epigenetic evaluations in cancer risk assessment.
Koturbash I; Beland FA; Pogribny IP
Toxicol Mech Methods; 2011 May; 21(4):289-97. PubMed ID: 21495867
[TBL] [Abstract][Full Text] [Related]
36. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
[TBL] [Abstract][Full Text] [Related]
37. Interplay between DNA damage repair and apoptosis shapes cancer evolution through aneuploidy and microsatellite instability.
Auslander N; Wolf YI; Koonin EV
Nat Commun; 2020 Mar; 11(1):1234. PubMed ID: 32144251
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic drivers of tumourigenesis and cancer metastasis.
Chatterjee A; Rodger EJ; Eccles MR
Semin Cancer Biol; 2018 Aug; 51():149-159. PubMed ID: 28807546
[TBL] [Abstract][Full Text] [Related]
39. Identifying driver mutations from sequencing data of heterogeneous tumors in the era of personalized genome sequencing.
Zhang J; Liu J; Sun J; Chen C; Foltz G; Lin B
Brief Bioinform; 2014 Mar; 15(2):244-55. PubMed ID: 23818492
[TBL] [Abstract][Full Text] [Related]
40. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.
Johansson P; Aoude LG; Wadt K; Glasson WJ; Warrier SK; Hewitt AW; Kiilgaard JF; Heegaard S; Isaacs T; Franchina M; Ingvar C; Vermeulen T; Whitehead KJ; Schmidt CW; Palmer JM; Symmons J; Gerdes AM; Jönsson G; Hayward NK
Oncotarget; 2016 Jan; 7(4):4624-31. PubMed ID: 26683228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
